Sickle Cell Disease
Conditions
Keywords
Sickle Cell, Hematopoietic Cell Transplant
Brief summary
The purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survival (GRFS) to greater than 90% after haploidentical donor HCT in children and young adults with SCD. Primary Objective: \- To assess the GVHD-free and rejection free survival (GRFS) after haploidentical donor HCT in children and young adults with SCD. Secondary Objectives: * Assess the overall survival (OS) and disease-free survival (DFS) after haploidentical donor HCT for SCD. * Estimate incidence and severity of acute and chronic GVHD after haploidentical donor HCT for SCD. * Assess the neutrophil and platelet engraftment kinetics after haploidentical donor HCT for SCD.
Interventions
IV
DRUGAbatacept
IV
DRUGAlemtuzumab
IV
DRUGHydroxyurea
IV
DRUGThiotepa
IV
DRUGFilgrastim
IV
DRUGSirolimus
IV
DRUGAzathioprine
IV
RADIATIONTBI
Radiaiton therapy
PROCEDUREHematopoietic Progenitor Cell Infusion
Hematopoietic Progenitor Cell Infusion
Sponsors
St. Jude Children's Research Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 22 Years
Healthy volunteers
No
Inclusion criteria
Transplant Recipient * Age less than or equal to 22 years. * Patients without a suitable HLA-matched sibling donor but with a suitable single haplotype matched (≥ 3 of 6) family member donor. Potential donors do not need to undergo eligibility determination prior to the recipients enrolling on the study. As long as a potential donor is identified and willing to donate hematopoietic progenitor cells, recipients can enroll on the study. * Patients with SCD (any genotype) who meet any ONE of the following criteria: * History of an abnormal transcranial Doppler measurement defined as TCD velocity ≥200 cm/sec by the non-imaging technique (or ≥185 cm/sec by the imaging technique) measured at a minimum of two separate occasions. * History of cerebral infarction on brain MRI (overt stroke, or silent cerebral infarct). * History of two or more episodes of acute chest syndrome (ACS) in the 2-years period preceding enrollment. * History of two or more SCD related pain events requiring treatment with parenteral analgesics in the last 12 months. * History of two or more episodes of priapism (erection lasting ≥4 hours or requiring emergent medical care). * Administration of regular RBC transfusions (≥8 transfusions in the previous 12 months). * Evidence of progressive end organ damage (eg. cardiomyopathy, nephropathy, pulmonary hypertension etc) that in the opinion of the treating hematologist is not responsive to medical management and may benefit from an HCT. Such a determination must be made in writing by at least two independent hematologists and documented in the patient's electronic medical record prior to enrollment. Donor * An at least single haplotype matched (≥ 3 of 6) family member. * HIV negative * Not pregnant, as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female). * Not breast feeding. * Donor should not have clinically significant hemoglobinopathy. Donors with sickle cell trait are acceptable. * Regarding donation eligibility, is identified as either: * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR. * Does not meet 21 CFR 1271 eligibility requirements but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.
Exclusion criteria
Transplant Recipient * Karnofsky or Lansky performance score \<60. * Pregnant, as confirmed by positive serum or urine pregnancy test within 14 days prior to enrollment (if female). * Breast feeding. * Uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning. Patients with febrile illness or suspected minor infection should await clinical resolution prior to starting conditioning. Patients with confirmed seropositivity or positive NAAT for HIV are excluded. * Serum conjugated (direct) bilirubin \>3x upper limit of normal for age as per local laboratory. Participants with hyperbilirubinemia as the result of hyperhemolysis, or a severe drop in hemoglobin post blood transfusion, are not excluded as long as it downtrends and return to acceptable limits subsequently. * Left ventricular shortening fraction \<25% or ejection fraction \<40% by echocardiogram. * Estimated creatinine clearance less than 50 mL/min/1.73m2. * Diffusion capacity of carbon monoxide (DLCO) \<35% (adjusted for hemoglobin) OR baseline oxygen saturation \<85% or PaO2 \<70. * Presence of anti-donor specific HLA antibodies unresponsive to desensitization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GVHD-free and rejection free survival (GRFS) | Up to 3 years after HCT | GRFS is defined as the time interval from transplant (graft infusion) until the first of grade III-IV acute GVHD, moderate or severe chronic GVHD, primary or secondary graft failure requiring second definitive therapy, and death occurs. GRFS will be calculated at 1-year, and 3-year post-transplant and reported as a percentage of the enrolled patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | Up to 3 years after HCT | Event for OS will include death due to any cause. OS will be evaluated and reported at 1 year and 3 years after HCT as a percentage of the enrolled patients. |
| Disease-free survival (DFS) | Up to 3 years after HCT | Events for DFS will include death due to any cause and recurrence of SCD symptoms or graft failure after HCT. DFS will be evaluated and reported at 1 year and 3 years after HCT as a percentage of the enrolled patients. |
| Incidence and severity of acute and chronic GVHD | Up to 3 years after HCT | Incidence of acute GVHD will be evaluated and reported at 1 month and, 3 months, and 6 months after HCT as a percentage of the enrolled patients. Incidence of chronic GVHD will be evaluated and reported at 6 months, 1 year and 3 years after HCT as a percentage of the enrolled patients |
| Neutrophil and platelet engraftment | Up to 6 months after HCT | The time to neutrophil and platelet engraftment will be reported in aggregate for all the participants using summary statistics. |
Countries
United States
Contacts
CONTACTAkshay Sharma, MD
PRINCIPAL_INVESTIGATORAkshay Sharma, MD
St. Jude Children's Research Hospital
Outcome results
None listed